Steven Cohen's AXSM Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 17,999 shares of Axsome Therapeutics, Inc. (AXSM) worth $3.29 M, representing 0.00% of the portfolio. First purchased in 2018-Q4, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in AXSM, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2020, adding 684,254 shares. Largest reduction occurred in Q2 2023, reducing 701,824 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Axsome Therapeutics (AXSM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Axsome Therapeutics (AXSM) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -715 | Reduce 3.82% | 17,999 | $182.64 |
| Q3 2025 | -332,259 | Reduce 94.67% | 18,714 | $121.45 |
| Q2 2025 | +224,780 | Add 178.12% | 350,973 | $104.39 |
| Q1 2025 | -58,945 | Reduce 31.84% | 126,193 | $116.63 |
| Q4 2024 | -357,482 | Reduce 65.88% | 185,138 | $84.61 |
| Q3 2024 | +63,576 | Add 13.27% | 542,620 | $89.87 |
| Q2 2024 | +100,180 | Add 26.44% | 479,044 | $80.50 |
| Q1 2024 | -458,337 | Reduce 54.75% | 378,864 | $79.80 |
| Q4 2023 | +305,264 | Add 57.39% | 837,201 | $79.59 |
| Q3 2023 | +63,934 | Add 13.66% | 531,937 | $69.89 |
| Q2 2023 | -701,824 | Reduce 59.99% | 468,003 | $71.86 |
| Q1 2023 | +519,762 | Add 79.96% | 1.17 M | $61.68 |
| Q4 2022 | +32,165 | Add 5.21% | 650,065 | $77.13 |
| Q3 2022 | +576,125 | Add 1379.11% | 617,900 | $44.62 |
| Q2 2022 | +41,775 | New Buy | 41,775 | $38.30 |
| Q2 2021 | -42,300 | Sold Out | 0 | $0.00 |
| Q1 2021 | -35,200 | Reduce 45.42% | 42,300 | $56.62 |
| Q4 2020 | -13,157 | Reduce 14.51% | 77,500 | $81.47 |
| Q3 2020 | -168,740 | Reduce 65.05% | 90,657 | $71.25 |
| Q2 2020 | -424,857 | Reduce 62.09% | 259,397 | $82.28 |
| Q1 2020 | +684,254 | New Buy | 684,254 | $58.83 |
| Q4 2019 | -160,000 | Sold Out | 0 | $0.00 |
| Q3 2019 | +160,000 | New Buy | 160,000 | $20.24 |
| Q1 2019 | -250,000 | Sold Out | 0 | $0.00 |
| Q4 2018 | +250,000 | New Buy | 250,000 | $2.82 |
Steven Cohen's Axsome Therapeutics Investment FAQs
Steven Cohen first purchased Axsome Therapeutics, Inc. (AXSM) in Q4 2018, acquiring 250,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Axsome Therapeutics, Inc. (AXSM) for 25 quarters since Q4 2018.
Steven Cohen's largest addition to Axsome Therapeutics, Inc. (AXSM) was in Q1 2020, adding 684,254 shares worth $40.26 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 17,999 shares of Axsome Therapeutics, Inc. (AXSM), valued at approximately $3.29 M.
As of the Q4 2025 filing, Axsome Therapeutics, Inc. (AXSM) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Axsome Therapeutics, Inc. (AXSM) was 1,169,827 shares, as reported at the end of Q1 2023.